{"id":"NCT01646177","sponsor":"Eli Lilly and Company","briefTitle":"A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)","officialTitle":"A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07-28","primaryCompletion":"2014-05-22","completion":"2019-07-22","firstPosted":"2012-07-20","resultsPosted":"2016-10-21","lastUpdate":"2020-07-28"},"enrollment":1346,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"50 mg etanercept","otherNames":[]},{"type":"DRUG","name":"80 mg ixekizumab","otherNames":["LY2439821"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"50 mg etanercept","type":"ACTIVE_COMPARATOR"},{"label":"80 mg ixekizumab Dosing Regimen 2","type":"EXPERIMENTAL"},{"label":"80 mg ixekizumab Dosing Regimen 1","type":"EXPERIMENTAL"}],"summary":"This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.","primaryOutcome":{"measure":"Number of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)","timeFrame":"Week 12","effectByArm":[{"arm":"Placebo","deltaMin":13,"sd":null},{"arm":"50 mg Etanercept","deltaMin":159,"sd":null},{"arm":"80 mg Ixekizumab Dosing Regimen 2 (Q4W)","deltaMin":291,"sd":null},{"arm":"80 mg Ixekizumab Dosing Regimen 1 (Q2W)","deltaMin":310,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":11},"locations":{"siteCount":101,"countries":["United States","Argentina","Bulgaria","Canada","Chile","Germany","Hungary","Mexico","Poland","Russia"]},"refs":{"pmids":["38647975","38521874","37400681","35279805","33253833","32845588","30465321","29751001","28074446","27910156","27299809","26953848","26072109"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":193},"commonTop":["Nasopharyngitis","Injection site reaction","Upper respiratory tract infection","Arthralgia","Headache"]}}